Overview

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Status:
Active, not recruiting

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well sorafenib works with carboplatin and paclitaxel in treating participants with head and neck squamous cell cancer that has spread to other parts of the body or that has come back. Drugs used in chemotherapy, such as sorafenib, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Bayer
National Cancer Institute (NCI)

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Niacinamide
Paclitaxel
Sorafenib